Quince Therapeutics, Inc. (QNCX) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
601 Gateway Blvd
South San Francisco, CA 94080
United States of America (the)
Phone
415 910 5717
Website
Sector
Healthcare
Industry
Biotechnology
Employees
36
First IPO Date
May 09, 2019
| Name | Title | Pay | Year Born |
| Dirk Thye | Chief Executive Officer, Chief Medical Officer & Director | 849,625 | 1970 |
| Brendan Hannah | Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial & Accounting Officer | 646,575 | 1986 |
| Charles S. Ryan | President | 733,100 | 1964 |
| Guenter R. Janhofer | Chief Scientific Officer | 0 | N/A |
| Giovanni Mambrini | Chief Technology Officer | 0 | N/A |
| Brigette Roberts | Chief Corporate Affairs Officer & Director | 0 | 1975 |
| Stewart A. Low | Head of Discovery | 0 | N/A |
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.